PPARA and metabolic dysfunction-associated steatotic liver disease: Lanifibranor (IVA337) is a pan-PPAR agonist with moderate and balanced effects on PPARα (on hepatocytes), PPARδ (on macrophages), and PPARγ (on stellate cells) that can ameliorate all aspects of NAFLD (Lefere et al., 2020).